Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Ross Osborn reiterates CVRx (NASDAQ:CVRX) with a Overweight and maintains $11 price target.
CVRx (NASDAQ:CVRX) sees Q3 sales of $13.700 million-$14.700 million vs $14.537 million analyst estimate.
CVRx (NASDAQ:CVRX) narrows FY2025 sales outlook from $55.000 million-$58.000 million to $55.000 million-$57.000 million vs $56....
CVRx (NASDAQ:CVRX) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.53) by 7.5...
CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medi...
Piper Sandler analyst Matt O'Brien maintains CVRx (NASDAQ:CVRX) with a Overweight and lowers the price target from $20 t...
